Publicaciones en las que colabora con M. LLamas Velasco (33)

2024

  1. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

    International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511

  2. Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 10-20

  3. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

    Actas Dermo-Sifiliograficas

  4. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

2023

  1. Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

    JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501

  2. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  3. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  4. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

  5. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  6. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology

  7. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 10, pp. 2004-2015

2022

  1. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study

    Dermatologic Therapy

  2. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

  3. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting

    Dermatologic Therapy, Vol. 35, Núm. 8

  4. Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness

    Expert Opinion on Biological Therapy

  5. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

    Dermatologic Therapy, Vol. 35, Núm. 12

  6. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

    Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117

  7. Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life

    Dermatologic Therapy, Vol. 35, Núm. 10

  8. Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population

    Journal of the European Academy of Dermatology and Venereology

2021

  1. Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

    Acta dermato-venereologica, Vol. 101, Núm. 1, pp. adv00354